title: Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin.
abstract: BACKGROUND
  The recent swine-origin H1N1 pandemic illustrates the need to develop improved procedures for rapid production of influenza vaccines. One alternative to the current egg-based manufacture of influenza vaccine is to produce a hemagglutinin (HA) subunit vaccine using a recombinant expression system with the potential for high protein yields, ease of cloning new antigenic variants, and an established safety record in humans.
  
  
  RESULTS
  We generated a soluble HA (sHA), derived from the H3N2 virus A/Aichi/2/68, modified at the C-terminus with a GCN4pII trimerization repeat to stabilize the native trimeric structure of HA. When expressed in the baculovirus system, the modified sHA formed native trimers. In contrast, the unmodified sHA was found to present epitopes recognized by a low-pH conformation specific monoclonal antibody. We found that mice primed and boosted with 3 microg of trimeric sHA in the absence of adjuvants had significantly higher IgG and HAI titers than mice that received the unmodified sHA. This correlated with an increased survival and reduced body weight loss following lethal challenge with mouse-adapted A/Aichi/2/68 virus. In addition, mice receiving a single vaccination of the trimeric sHA in the absence of adjuvants had improved survival and body weight loss compared to mice vaccinated with the unmodified sHA.
  
  
  CONCLUSIONS
  Our data indicate that the recombinant trimeric sHA presents native trimeric epitopes while the unmodified sHA presents epitopes not exposed in the native HA molecule. The epitopes presented in the unmodified sHA constitute a "silent face" which may skew the antibody response to epitopes not accessible in live virus at neutral pH. The results demonstrate that the trimeric sHA is a more effective influenza vaccine candidate and emphasize the importance of structure-based antigen design in improving recombinant HA vaccines.
authors.affiliation: Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, United States of America.
authors.forename: William C
authors.initials: WC
authors.lastname: Weldon
authors.forename: Bao-Zhong
authors.initials: BZ
authors.lastname: Wang
authors.forename: Maria P
authors.initials: MP
authors.lastname: Martin
authors.forename: Dimitrios G
authors.initials: DG
authors.lastname: Koutsonanos
authors.forename: Ioanna
authors.initials: I
authors.lastname: Skountzou
authors.forename: Richard W
authors.initials: RW
authors.lastname: Compans
mesh_terms: D000818:Animals; D005260:Female; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D006801:Humans; D053122:Influenza A Virus, H3N2 Subtype / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D007252:Influenza Vaccines / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology / Q000821:virology*; D051379:Mice; D008807:Mice, Inbred BALB C; D055503:Protein Multimerization; D055550:Protein Stability; D012995:Solubility
chemical_list: D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines
references.citation: Nature. 2009 Jun 18;459(7249):931-9
references.pmid: 19525932
references.citation: Vaccine. 1999 Apr 9;17(15-16):2073-80
references.pmid: 10217609
references.citation: Nat Biotechnol. 2005 May;23(5):567-75
references.pmid: 15877075
references.citation: Vaccine. 2006 Mar 15;24(12):2176-85
references.pmid: 16310896
references.citation: Vaccine. 2001 Feb 8;19(13-14):1732-7
references.pmid: 11166898
references.citation: Vaccine. 2007 Sep 28;25(39-40):6852-62
references.pmid: 17719149
references.citation: J Virol. 2007 Oct;81(20):10869-78
references.pmid: 17670815
references.citation: Virology. 2005 Sep 1;339(2):273-80
references.pmid: 15996702
references.citation: Annu Rev Immunol. 1990;8:303-33
references.pmid: 1693082
references.citation: Vaccine. 1999 May 4;17(18):2265-74
references.pmid: 10403594
references.citation: Proc Natl Acad Sci U S A. 1982 Feb;79(4):968-72
references.pmid: 6951181
references.citation: Science. 1989 Jan 27;243(4890):538-42
references.pmid: 2911757
references.citation: Curr Top Microbiol Immunol. 2007;315:67-83
references.pmid: 17848061
references.citation: Annu Rev Immunol. 2000;18:709-37
references.pmid: 10837073
references.citation: Proc Natl Acad Sci U S A. 1970 Jul;66(3):651-6
references.pmid: 4913206
references.citation: Science. 1993 Nov 26;262(5138):1401-7
references.pmid: 8248779
references.citation: Nature. 1981 Jan 29;289(5796):366-73
references.pmid: 7464906
references.citation: J Exp Med. 1991 Apr 1;173(4):953-9
references.pmid: 1706753
references.citation: PLoS One. 2010 May 14;5(5):e10645
references.pmid: 20498717
references.citation: J Virol. 2005 Aug;79(15):9954-69
references.pmid: 16014956
references.citation: Immunol Rev. 1997 Oct;159:105-17
references.pmid: 9416506
references.citation: JAMA. 2007 Apr 11;297(14):1577-82
references.pmid: 17426277
references.citation: Vaccine. 2009 Nov 5;27(47):6589-94
references.pmid: 19716456
references.citation: Annu Rev Biochem. 1987;56:365-94
references.pmid: 3304138
references.citation: Vaccine. 2007 Apr 20;25(16):3062-5
references.pmid: 17276554
references.citation: Virology. 2010 Jul 20;403(1):17-25
references.pmid: 20441997
references.citation: Adv Exp Med Biol. 2008;632:187-201
references.pmid: 19025123
references.citation: Nature. 2006 Jan 5;439(7072):38-44
references.pmid: 16397490
references.citation: J Infect Dis. 2006 May 1;193(9):1223-8
references.pmid: 16586358
references.citation: J Virol. 2008 Jul;82(13):6200-8
references.pmid: 18417563
references.citation: J Hyg (Lond). 1972 Dec;70(4):767-77
references.pmid: 4509641
references.citation: Annu Rev Immunol. 1990;8:737-71
references.pmid: 2188678
references.citation: Vaccine. 1985 Sep;3(3 Suppl):175-81
references.pmid: 2414938
references.citation: J Gen Virol. 1988 Nov;69 ( Pt 11):2785-95
references.pmid: 3183628
references.citation: Arch Virol. 1996;141(9):1715-26
references.pmid: 8893793
references.citation: Annu Rev Biochem. 2000;69:531-69
references.pmid: 10966468
references.citation: J Virol. 2000 May;74(10):4746-54
references.pmid: 10775613
references.citation: Arch Virol. 1998;143(2):227-39
references.pmid: 9541609
references.citation: J Gen Virol. 1989 Apr;70 ( Pt 4):809-18
references.pmid: 2732707
references.citation: J Biol Chem. 2008 Apr 25;283(17):11382-7
references.pmid: 18252707
references.citation: Clin Vaccine Immunol. 2006 Sep;13(9):981-90
references.pmid: 16960108